Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Adherence | 28 | 2024 | 521 | 8.150 |
Why?
|
| Medicare Part C | 9 | 2024 | 32 | 5.350 |
Why?
|
| Motivational Interviewing | 7 | 2023 | 48 | 5.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2022 | 881 | 3.740 |
Why?
|
| Hypertension | 12 | 2023 | 1584 | 3.630 |
Why?
|
| Hyperlipidemias | 5 | 2022 | 247 | 3.390 |
Why?
|
| Diabetes Mellitus | 9 | 2023 | 1103 | 2.580 |
Why?
|
| Smoking Cessation | 7 | 2016 | 764 | 2.090 |
Why?
|
| Antihypertensive Agents | 5 | 2021 | 417 | 1.970 |
Why?
|
| Smoking | 8 | 2016 | 2522 | 1.500 |
Why?
|
| Medicare Part D | 2 | 2021 | 31 | 1.460 |
Why?
|
| Pharmaceutical Services | 3 | 2021 | 35 | 1.300 |
Why?
|
| United States | 32 | 2024 | 16312 | 1.150 |
Why?
|
| Medicare | 12 | 2024 | 925 | 1.130 |
Why?
|
| Anticoagulants | 3 | 2024 | 856 | 1.130 |
Why?
|
| Atrial Fibrillation | 3 | 2024 | 799 | 1.110 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 2352 | 1.050 |
Why?
|
| Bupropion | 2 | 2016 | 76 | 1.030 |
Why?
|
| Varenicline | 2 | 2016 | 71 | 1.030 |
Why?
|
| Angiotensin Receptor Antagonists | 6 | 2023 | 156 | 1.000 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2023 | 271 | 0.960 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2021 | 14 | 0.950 |
Why?
|
| Retrospective Studies | 39 | 2024 | 39457 | 0.940 |
Why?
|
| Antipsychotic Agents | 5 | 2024 | 428 | 0.840 |
Why?
|
| Obesity | 6 | 2023 | 2989 | 0.810 |
Why?
|
| Warfarin | 2 | 2022 | 159 | 0.800 |
Why?
|
| Aged | 36 | 2024 | 72685 | 0.780 |
Why?
|
| Students | 3 | 2013 | 332 | 0.770 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2019 | 1347 | 0.730 |
Why?
|
| Students, Pharmacy | 2 | 2019 | 60 | 0.700 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 75 | 0.680 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 118 | 0.680 |
Why?
|
| Texas | 14 | 2024 | 6457 | 0.670 |
Why?
|
| Hemorrhage | 1 | 2024 | 767 | 0.660 |
Why?
|
| Weight Gain | 3 | 2024 | 472 | 0.650 |
Why?
|
| Logistic Models | 11 | 2021 | 3517 | 0.650 |
Why?
|
| Benchmarking | 1 | 2020 | 289 | 0.610 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 185 | 0.610 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 310 | 0.590 |
Why?
|
| Humans | 70 | 2024 | 270303 | 0.580 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 366 | 0.570 |
Why?
|
| Hospitalization | 3 | 2020 | 2207 | 0.550 |
Why?
|
| Arabs | 1 | 2015 | 38 | 0.540 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 45 | 0.530 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 105 | 0.520 |
Why?
|
| Patient Readmission | 1 | 2020 | 593 | 0.510 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 130 | 0.500 |
Why?
|
| Drug Combinations | 4 | 2020 | 635 | 0.500 |
Why?
|
| Universities | 3 | 2013 | 163 | 0.500 |
Why?
|
| Health Care Costs | 1 | 2020 | 719 | 0.490 |
Why?
|
| Administration, Oral | 4 | 2024 | 1583 | 0.490 |
Why?
|
| Female | 47 | 2024 | 146977 | 0.490 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 120 | 0.480 |
Why?
|
| Primary Health Care | 1 | 2021 | 847 | 0.480 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 2347 | 0.480 |
Why?
|
| Tobacco Products | 1 | 2015 | 129 | 0.480 |
Why?
|
| Cancer Survivors | 2 | 2018 | 721 | 0.470 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2024 | 114 | 0.460 |
Why?
|
| Male | 38 | 2024 | 127343 | 0.460 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 293 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 1417 | 0.450 |
Why?
|
| Cross-Sectional Studies | 13 | 2022 | 4520 | 0.450 |
Why?
|
| Stroke | 1 | 2022 | 1190 | 0.440 |
Why?
|
| Telephone | 3 | 2019 | 162 | 0.430 |
Why?
|
| Pharmacists | 3 | 2020 | 91 | 0.430 |
Why?
|
| Schizophrenia | 1 | 2016 | 381 | 0.430 |
Why?
|
| Social Perception | 1 | 2013 | 74 | 0.410 |
Why?
|
| Breast Neoplasms | 10 | 2023 | 16050 | 0.410 |
Why?
|
| Risk-Taking | 2 | 2012 | 137 | 0.400 |
Why?
|
| Aged, 80 and over | 12 | 2024 | 30718 | 0.400 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2016 | 13 | 0.380 |
Why?
|
| Health Behavior | 1 | 2015 | 621 | 0.380 |
Why?
|
| Buprenorphine | 2 | 2022 | 100 | 0.370 |
Why?
|
| Middle Aged | 24 | 2024 | 89347 | 0.370 |
Why?
|
| Nicotine | 1 | 2013 | 262 | 0.360 |
Why?
|
| Social Class | 2 | 2024 | 325 | 0.320 |
Why?
|
| Hydrocodone | 2 | 2019 | 52 | 0.300 |
Why?
|
| Physicians | 4 | 2019 | 913 | 0.290 |
Why?
|
| Patient Compliance | 2 | 2015 | 682 | 0.290 |
Why?
|
| Hypoglycemic Agents | 2 | 2022 | 607 | 0.290 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 412 | 0.280 |
Why?
|
| Disease Management | 1 | 2012 | 1102 | 0.270 |
Why?
|
| Young Adult | 12 | 2024 | 22092 | 0.270 |
Why?
|
| Polypharmacy | 1 | 2005 | 61 | 0.260 |
Why?
|
| Adult | 24 | 2024 | 80561 | 0.250 |
Why?
|
| Body Mass Index | 6 | 2024 | 2289 | 0.250 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 29 | 0.250 |
Why?
|
| Dabigatran | 1 | 2024 | 28 | 0.240 |
Why?
|
| Adolescent | 14 | 2024 | 32284 | 0.240 |
Why?
|
| Rivaroxaban | 1 | 2024 | 61 | 0.230 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 848 | 0.230 |
Why?
|
| Factor Xa Inhibitors | 1 | 2024 | 79 | 0.220 |
Why?
|
| Hypolipidemic Agents | 1 | 2004 | 197 | 0.210 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2022 | 28 | 0.210 |
Why?
|
| Confidence Intervals | 3 | 2013 | 769 | 0.210 |
Why?
|
| Aromatase Inhibitors | 3 | 2020 | 312 | 0.210 |
Why?
|
| Ambulatory Care | 2 | 2020 | 578 | 0.200 |
Why?
|
| Medicaid | 2 | 2021 | 310 | 0.200 |
Why?
|
| Risk Factors | 8 | 2024 | 18226 | 0.200 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2022 | 86 | 0.200 |
Why?
|
| Pharmacies | 1 | 2021 | 13 | 0.190 |
Why?
|
| Pyridones | 1 | 2024 | 366 | 0.190 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 111 | 0.190 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 5114 | 0.190 |
Why?
|
| Pharmacy | 1 | 2021 | 15 | 0.190 |
Why?
|
| Thalidomide | 1 | 2024 | 577 | 0.180 |
Why?
|
| Controlled Substances | 2 | 2019 | 14 | 0.180 |
Why?
|
| Neomycin | 1 | 2020 | 36 | 0.180 |
Why?
|
| Health Surveys | 2 | 2012 | 414 | 0.180 |
Why?
|
| Lactulose | 1 | 2020 | 38 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2022 | 318 | 0.180 |
Why?
|
| HIV Infections | 3 | 2023 | 2215 | 0.170 |
Why?
|
| Cognition Disorders | 1 | 2005 | 787 | 0.170 |
Why?
|
| Markov Chains | 1 | 2020 | 183 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 15176 | 0.170 |
Why?
|
| Sexual Behavior | 2 | 2013 | 316 | 0.170 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 119 | 0.170 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 242 | 0.170 |
Why?
|
| Psychological Theory | 2 | 2016 | 48 | 0.170 |
Why?
|
| Military Personnel | 2 | 2013 | 236 | 0.170 |
Why?
|
| Acute Pain | 1 | 2019 | 49 | 0.170 |
Why?
|
| Comorbidity | 2 | 2016 | 2454 | 0.160 |
Why?
|
| Odds Ratio | 3 | 2013 | 2361 | 0.160 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 233 | 0.160 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 5913 | 0.160 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 379 | 0.160 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 590 | 0.160 |
Why?
|
| Sex Factors | 2 | 2019 | 2214 | 0.160 |
Why?
|
| Metformin | 1 | 2022 | 390 | 0.160 |
Why?
|
| Intention | 2 | 2016 | 119 | 0.160 |
Why?
|
| Tamoxifen | 2 | 2020 | 883 | 0.160 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 550 | 0.160 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 1422 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2022 | 1280 | 0.150 |
Why?
|
| Forecasting | 1 | 2021 | 708 | 0.150 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 273 | 0.150 |
Why?
|
| Health Services | 1 | 2018 | 108 | 0.150 |
Why?
|
| Health Care Surveys | 2 | 2019 | 444 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 617 | 0.140 |
Why?
|
| Standard of Care | 1 | 2018 | 267 | 0.140 |
Why?
|
| Middle East | 2 | 2016 | 46 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2019 | 625 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2022 | 744 | 0.140 |
Why?
|
| Perception | 2 | 2022 | 358 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 891 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 982 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2021 | 1852 | 0.130 |
Why?
|
| Health Planning Guidelines | 1 | 2016 | 58 | 0.130 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 57 | 0.130 |
Why?
|
| Chronic Pain | 1 | 2019 | 255 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2023 | 912 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 38 | 0.130 |
Why?
|
| Smoking Prevention | 1 | 2016 | 144 | 0.130 |
Why?
|
| Quinolines | 1 | 2019 | 396 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 397 | 0.130 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 344 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2024 | 1517 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 637 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 833 | 0.120 |
Why?
|
| Blood Glucose | 3 | 2023 | 1266 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 6269 | 0.120 |
Why?
|
| Age Factors | 2 | 2019 | 5489 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 1102 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 4384 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2020 | 2837 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2019 | 13265 | 0.110 |
Why?
|
| Propylene Glycol | 1 | 2013 | 10 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2019 | 1526 | 0.110 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2013 | 70 | 0.110 |
Why?
|
| Social Values | 1 | 2013 | 62 | 0.110 |
Why?
|
| Pakistan | 1 | 2012 | 76 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 807 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 2235 | 0.100 |
Why?
|
| Jordan | 1 | 2012 | 24 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 111 | 0.100 |
Why?
|
| India | 1 | 2012 | 306 | 0.100 |
Why?
|
| Opiate Substitution Treatment | 2 | 2022 | 32 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 203 | 0.100 |
Why?
|
| Focus Groups | 1 | 2013 | 281 | 0.100 |
Why?
|
| Sunlight | 1 | 2011 | 80 | 0.100 |
Why?
|
| Recurrence | 1 | 2020 | 4877 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2018 | 9471 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 1997 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 10254 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 146 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 494 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 4884 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 121 | 0.090 |
Why?
|
| Health Personnel | 1 | 2016 | 648 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 640 | 0.090 |
Why?
|
| Self Report | 1 | 2014 | 781 | 0.090 |
Why?
|
| Child | 7 | 2024 | 30149 | 0.090 |
Why?
|
| Cholesterol | 2 | 2023 | 680 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 1047 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 267 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 308 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 815 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 2616 | 0.080 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 29 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 3091 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 1334 | 0.070 |
Why?
|
| Incidence | 1 | 2015 | 5886 | 0.060 |
Why?
|
| New England | 1 | 2004 | 17 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2005 | 184 | 0.060 |
Why?
|
| Aripiprazole | 1 | 2024 | 21 | 0.060 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2023 | 30 | 0.060 |
Why?
|
| Cholinergic Antagonists | 1 | 2024 | 61 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2004 | 131 | 0.060 |
Why?
|
| Patient Acuity | 1 | 2023 | 76 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2022 | 34144 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2023 | 6231 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2005 | 368 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2022 | 77 | 0.050 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 45 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 1569 | 0.050 |
Why?
|
| Nigeria | 2 | 2013 | 74 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2023 | 131 | 0.050 |
Why?
|
| Mortality | 1 | 2004 | 374 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 149 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 267 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 16258 | 0.050 |
Why?
|
| Sexual Partners | 2 | 2013 | 111 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 3960 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 328 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 379 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2024 | 667 | 0.040 |
Why?
|
| Research | 1 | 2023 | 436 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2004 | 811 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2022 | 217 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 3518 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 256 | 0.040 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 956 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 661 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 2049 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 990 | 0.040 |
Why?
|
| United States Government Agencies | 1 | 2016 | 9 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 400 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 170 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 53 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2023 | 2316 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1415 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2353 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2013 | 39 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1625 | 0.030 |
Why?
|
| Mastectomy | 1 | 2020 | 1557 | 0.030 |
Why?
|
| Breast | 1 | 2020 | 1362 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2122 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 968 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 1022 | 0.020 |
Why?
|
| SEER Program | 1 | 2015 | 1012 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 55 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2015 | 1965 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 212 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 2278 | 0.020 |
Why?
|
| Neoplasms | 1 | 2016 | 15695 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 645 | 0.020 |
Why?
|
| Survival Rate | 1 | 2023 | 12429 | 0.020 |
Why?
|
| Mammography | 1 | 2015 | 1030 | 0.020 |
Why?
|
| Communication | 1 | 2016 | 908 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 300 | 0.020 |
Why?
|
| Cisplatin | 1 | 2015 | 2456 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 16762 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 1263 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 13879 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 3397 | 0.010 |
Why?
|
| Heart Failure | 1 | 2016 | 2658 | 0.010 |
Why?
|